What's Left after Mensing

 

 

Mensing changed the landscape of litigation against manufacturers of generic drugs. This program will examine the decision and its aftermath; in particular, whether it has brought the type of sweeping results that many predicted. In addition, this program will discuss plaintiffs’ efforts to circumvent Mensing, the decision’s potential impact on generic manufacturer responsibilities, and what the future might hold for generic drug product liability cases. The program will also provide an update on Mensing-related cases, including a review of the U.S. Supreme Court argument in Bartlett, which is scheduled for March.

Published
Tue, 2013-04-09

Mark C. Hegarty, partner in Shook Hardy & Bacon LLP; Mary Nold Larimore, partner in Ice Miller LLP; Michael J. Miller, partner in Strong & Hanni

1-2:30 pm Central
$180
TBA

(877) 880-1335 or email support@inreachce.com